Cornelius Mccarthy III Sells 1,140 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Cornelius Mccarthy III sold 1,140 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $605.37, for a total transaction of $690,121.80. Following the completion of the sale, the director directly owned 12,275 shares of the company’s stock, valued at $7,430,916.75. The trade was a 8.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Medpace Stock Down 2.5%

MEDP stock traded down $15.03 during trading on Thursday, hitting $581.95. 151,058 shares of the company’s stock traded hands, compared to its average volume of 353,878. The firm has a market capitalization of $16.24 billion, a P/E ratio of 34.11, a PEG ratio of 2.70 and a beta of 1.15. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The business has a fifty day simple moving average of $531.28 and a two-hundred day simple moving average of $491.78.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter last year, the firm earned $3.10 EPS. The business’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Institutional Trading of Medpace

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in Medpace in the 2nd quarter worth approximately $1,323,047,000. AQR Capital Management LLC increased its stake in Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares in the last quarter. Madison Asset Management LLC acquired a new position in Medpace during the 2nd quarter valued at approximately $128,956,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after buying an additional 211,411 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in shares of Medpace by 158.6% in the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after buying an additional 183,645 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and lifted their target price for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. TD Cowen increased their price target on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Truist Financial raised their price target on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Finally, BMO Capital Markets boosted their price objective on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Two investment analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.